Skip to main content

01-01-2015 | Renal cell carcinoma | Article

22. Toxicity Management of Renal Cell Cancer Patients on Targeted Therapies

Authors: MD, FRCPC Christian Kollmannsberger, G. A. Bjarnason, Alain Ravaud

Publisher: Springer International Publishing


Targeted therapies have significantly changed the treatment landscape for patients with metastatic renal cell carcinoma (mRCC). TKIs such as sunitinib, sorafenib, pazopanib, and axitinib are all multi-targeted inhibitors which inhibit a variety of targets including the vascular endothelial growth factor receptors 1, 2, and 3, platelet-derived growth factor receptor (PDGFR), and others. Temsirolimus and everolimus both interfere with angiogenesis by inhibiting mTOR, a critical regulator within the cell. Bevacizumab blocks the vascular endothelial growth factor (VEGF) pathway by binding to VEGF.

Please log in to get access to this content

Related topics